Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy
BackgroundImmune checkpoint blockade (ICB) has improved outcomes for a subset of colorectal cancer (CRC) patients, yet the cellular determinants that drive heterogeneous treatment responses remain insufficiently understood. The extent to which ICB resh…